SSII to Host Global Robotic Surgery Conference

By Chris Stiles • Tuesday, April 07 16:20 • Permanent Link

SS Innovations said its Global Multi-Specialty Robotic Surgery Conference 2026 will run April 9-11 in New Delhi, expanding on last year’s event, which drew more than 1,400 attendees and 600 virtual participants from 17 nations.

This year’s conference will feature more than 20 live telesurgeries using the SSI Mantra surgical robotic system, along with several procedures using the SSI MantraSana tele surgeon console, a chair-based version of the larger command center.

The company also plans to showcase the SSI Vimana Aero, a drone-deployed trauma surgery system under development. The platform is designed to be delivered by heavy-lift autonomous drone and equipped with two miniature robotic arms with seven degrees of freedom and 5mm surgical instruments. It is intended to support procedures including hemorrhage control, wound repair, chest decompression, shrapnel extraction and field suturing.

Other displays include Project Operion, described as a mobile operating-room concept on wheels, and the Mantram mobile robotic telesurgery unit, or “Mantram bus,” aimed at bringing robotic surgical care and training to remote locations.

Conference sessions will cover urology, thoracic, gastroenterology, head and neck, gynecology, colorectal, general and pediatric surgery, plus separate cardiac-focused breakout sessions.

Among the featured guests are Dr. Fred Moll, vice-chairman of SS Innovations; Sri Madhusudan Sai; Dr. Naresh Trehan; Dr. Mylswamy Annadurai; and Dr. Ashutosh Tewari.

The company said this year’s event will be its largest to date. Following these announcements, the company's shares moved 1.44%, and are now trading at a price of $4.93. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.